Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Pioneer Pharma Completes $2.5 Million Investment in NovaBay

publication date: Nov 5, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Pioneer Pharma, a Singapore company that is affiliated with Naqu Area Pioneer Pharma of Shanghai, completed a $2.5 million investment into California-based NovaBay® Pharma. The investment was part of deal that gives Pioneer the right to market NovaBay’s anti-infective wound-cleaning product, NeutroPhase, in China and Southeast Asia. The investment purchased two million units at a price of $1.25 each. Each unit consists of one share of NovaBay and a warrant to buy an additional share at a price of $1.50. NovaBay is currently trading at $1.31. More details....

Stock Symbol: (NYSE: NBY)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...



Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China

>>More events...
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Partners